Literature DB >> 21039416

Pharmacological characterization of six trkB antibodies reveals a novel class of functional agents for the study of the BDNF receptor.

M Cazorla1, J M Arrang, J Prémont.   

Abstract

BACKGROUND AND
PURPOSE: By interacting with trkB receptors, brain-derived neurotrophic factor (BDNF) triggers various signalling pathways responsible for neurone survival, differentiation and modulation of synaptic transmission. Numerous reports have implicated BDNF and trkB in the pathogenesis of various central nervous system affections and in cancer, thus representing trkB as a promising therapeutic target. In this study, we used an antibody-based approach to search for trkB-selective functional reagents. EXPERIMENTAL APPROACH: Six commercially available polyclonal and monoclonal antibodies were tested on recombinant and native, human and rodent trkB receptors. Functional and pharmacological characterization was performed using a modified version of the KIRA-elisa method and radioligand binding studies. Western blot analyses and neurite outgrowth assays were carried out to determine the specificity and selectivity of antibody effects. The survival properties of one antibody were further assessed on cultured neurones in a serum-deprived paradigm. KEY
RESULTS: The functional trkB-selective antibodies showed distinct pharmacological profiles, ranging from partial agonists to antagonists, acting on trkB receptors through allosteric modulations. The same diversity of effects was observed on the mitogen-activated protein kinase signalling pathway downstream of trkB and on the subsequent neurite outgrowth. One antibody with partial agonist activity demonstrated cell survival properties by activating the Akt pathway. Finally, these antibodies were functionally validated as true trkB-selective ligands because they failed activating trkA or trkC, and contrary to BDNF, none of them bind to p75(NTR). CONCLUSIONS AND IMPLICATIONS: These trkB-selective antibodies represent a novel class of pharmacological tools to explore the pathophysiological roles of trkB and its potential therapeutic relevance for the treatment of various disorders.
© 2011 The Authors. British Journal of Pharmacology © 2011 The British Pharmacological Society.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21039416      PMCID: PMC3042204          DOI: 10.1111/j.1476-5381.2010.01094.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  40 in total

Review 1.  Neurotrophins as synaptic modulators.

Authors:  M M Poo
Journal:  Nat Rev Neurosci       Date:  2001-01       Impact factor: 34.870

Review 2.  Neurotrophins: roles in neuronal development and function.

Authors:  E J Huang; L F Reichardt
Journal:  Annu Rev Neurosci       Date:  2001       Impact factor: 12.449

Review 3.  Trk receptors: roles in neuronal signal transduction.

Authors:  Eric J Huang; Louis F Reichardt
Journal:  Annu Rev Biochem       Date:  2003-03-27       Impact factor: 23.643

Review 4.  Neurotrophins and their receptors: a convergence point for many signalling pathways.

Authors:  Moses V Chao
Journal:  Nat Rev Neurosci       Date:  2003-04       Impact factor: 34.870

5.  Specificity in Trk receptor:neurotrophin interactions: the crystal structure of TrkB-d5 in complex with neurotrophin-4/5.

Authors:  M J Banfield; R L Naylor; A G Robertson; S J Allen; D Dawbarn; R L Brady
Journal:  Structure       Date:  2001-12       Impact factor: 5.006

6.  Functional blockade of tyrosine kinase A in the rat basal forebrain by a novel antagonistic anti-receptor monoclonal antibody.

Authors:  A Cattaneo; S Capsoni; E Margotti; M Righi; E Kontsekova; P Pavlik; P Filipcik; M Novak
Journal:  J Neurosci       Date:  1999-11-15       Impact factor: 6.167

Review 7.  BDNF and activity-dependent synaptic modulation.

Authors:  Bai Lu
Journal:  Learn Mem       Date:  2003 Mar-Apr       Impact factor: 2.460

Review 8.  Neurobiology of depression.

Authors:  Eric J Nestler; Michel Barrot; Ralph J DiLeone; Amelia J Eisch; Stephen J Gold; Lisa M Monteggia
Journal:  Neuron       Date:  2002-03-28       Impact factor: 17.173

9.  Cyclotraxin-B, the first highly potent and selective TrkB inhibitor, has anxiolytic properties in mice.

Authors:  Maxime Cazorla; Anne Jouvenceau; Christiane Rose; Jean-Philippe Guilloux; Catherine Pilon; Alex Dranovsky; Joël Prémont
Journal:  PLoS One       Date:  2010-03-19       Impact factor: 3.240

10.  Loss of huntingtin-mediated BDNF gene transcription in Huntington's disease.

Authors:  C Zuccato; A Ciammola; D Rigamonti; B R Leavitt; D Goffredo; L Conti; M E MacDonald; R M Friedlander; V Silani; M R Hayden; T Timmusk; S Sipione; E Cattaneo
Journal:  Science       Date:  2001-06-14       Impact factor: 47.728

View more
  19 in total

Review 1.  Insulin-like Growth Factor-I Receptor and Thyroid-Associated Ophthalmopathy.

Authors:  Terry J Smith; Joseph A M J L Janssen
Journal:  Endocr Rev       Date:  2019-02-01       Impact factor: 19.871

2.  BDNF repairs podocyte damage by microRNA-mediated increase of actin polymerization.

Authors:  Min Li; Silvia Armelloni; Cristina Zennaro; Changli Wei; Alessandro Corbelli; Masami Ikehata; Silvia Berra; Laura Giardino; Deborah Mattinzoli; Shojiro Watanabe; Carlo Agostoni; Alberto Edefonti; Jochen Reiser; Piergiorgio Messa; Maria Pia Rastaldi
Journal:  J Pathol       Date:  2015-01-07       Impact factor: 7.996

3.  TrkB signalling pathway mediates the protective effects of exercise in the diabetic rat retina.

Authors:  Rachael S Allen; Adam M Hanif; Marissa A Gogniat; Brian C Prall; Raza Haider; Moe H Aung; Megan C Prunty; Lukas M Mees; Monica M Coulter; Cara T Motz; Jeffrey H Boatright; Machelle T Pardue
Journal:  Eur J Neurosci       Date:  2018-04-03       Impact factor: 3.386

4.  Genome-wide association for fear conditioning in an advanced intercross mouse line.

Authors:  Clarissa C Parker; Greta Sokoloff; Riyan Cheng; Abraham A Palmer
Journal:  Behav Genet       Date:  2012-01-12       Impact factor: 2.805

Review 5.  Neuroprotective strategies for retinal disease.

Authors:  Machelle T Pardue; Rachael S Allen
Journal:  Prog Retin Eye Res       Date:  2018-02-23       Impact factor: 21.198

6.  A fully human, allosteric monoclonal antibody that activates the insulin receptor and improves glycemic control.

Authors:  Vinay Bhaskar; Ira D Goldfine; Daniel H Bedinger; Angela Lau; Hua F Kuan; Lisa M Gross; Masahisa Handa; Betty A Maddux; Susan R Watson; Shirley Zhu; Ajay J Narasimha; Raphael Levy; Lynn Webster; Sujeewa D Wijesuriya; Naichi Liu; Xiaorong Wu; David Chemla-Vogel; Catarina Tran; Steve R Lee; Steve Wong; Diane Wilcock; Mark L White; John A Corbin
Journal:  Diabetes       Date:  2012-03-08       Impact factor: 9.461

7.  Nanoparticle mediated drug delivery of rolipram to tyrosine kinase B positive cells in the inner ear with targeting peptides and agonistic antibodies.

Authors:  Rudolf Glueckert; Christian O Pritz; Soumen Roy; Jozsef Dudas; Anneliese Schrott-Fischer
Journal:  Front Aging Neurosci       Date:  2015-05-19       Impact factor: 5.750

8.  A monoclonal antibody TrkB receptor agonist as a potential therapeutic for Huntington's disease.

Authors:  Daniel Todd; Ian Gowers; Simon J Dowler; Michael D Wall; George McAllister; David F Fischer; Sipke Dijkstra; Silvina A Fratantoni; Rhea van de Bospoort; Jessica Veenman-Koepke; Geraldine Flynn; Jamshid Arjomand; Celia Dominguez; Ignacio Munoz-Sanjuan; John Wityak; Jonathan A Bard
Journal:  PLoS One       Date:  2014-02-04       Impact factor: 3.240

9.  Tau-Driven Neuronal and Neurotrophic Dysfunction in a Mouse Model of Early Tauopathy.

Authors:  Nadia Mazzaro; Erica Barini; Maria Grazia Spillantini; Michel Goedert; Paolo Medini; Laura Gasparini
Journal:  J Neurosci       Date:  2016-02-17       Impact factor: 6.167

10.  Improved glucose metabolism in vitro and in vivo by an allosteric monoclonal antibody that increases insulin receptor binding affinity.

Authors:  John A Corbin; Vinay Bhaskar; Ira D Goldfine; Daniel H Bedinger; Angela Lau; Kristen Michelson; Lisa M Gross; Betty A Maddux; Hua F Kuan; Catarina Tran; Llewelyn Lao; Masahisa Handa; Susan R Watson; Ajay J Narasimha; Shirley Zhu; Raphael Levy; Lynn Webster; Sujeewa D Wijesuriya; Naichi Liu; Xiaorong Wu; David Chemla-Vogel; Steve R Lee; Steve Wong; Diane Wilcock; Mark L White
Journal:  PLoS One       Date:  2014-02-12       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.